Short Interest in Barinthus Biotherapeutics plc (NASDAQ:BRNS) Drops By 15.1%

Barinthus Biotherapeutics plc (NASDAQ:BRNS - Get Free Report) was the target of a large drop in short interest in March. As of March 31st, there was short interest totalling 10,100 shares, a drop of 15.1% from the March 15th total of 11,900 shares. Approximately 0.0% of the company's stock are short sold. Based on an average trading volume of 21,400 shares, the short-interest ratio is currently 0.5 days.

Analyst Ratings Changes

Several equities analysts have commented on BRNS shares. HC Wainwright dropped their price target on shares of Barinthus Biotherapeutics from $15.00 to $8.00 and set a "buy" rating on the stock in a research note on Thursday, March 21st. William Blair reissued an "outperform" rating on shares of Barinthus Biotherapeutics in a research report on Monday, January 8th.

Barinthus Biotherapeutics Stock Down 5.7 %

BRNS traded down $0.19 during trading on Friday, hitting $3.14. 2,700 shares of the stock were exchanged, compared to its average volume of 35,324. Barinthus Biotherapeutics has a 1-year low of $1.64 and a 1-year high of $5.10. The company's fifty day simple moving average is $2.69. The company has a market cap of $122.21 million, a price-to-earnings ratio of -1.64 and a beta of -0.52.

Barinthus Biotherapeutics (NASDAQ:BRNS - Get Free Report) last announced its earnings results on Wednesday, March 20th. The company reported ($0.45) EPS for the quarter, beating analysts' consensus estimates of ($0.55) by $0.10. On average, analysts forecast that Barinthus Biotherapeutics will post -2.6 EPS for the current fiscal year.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.